Treatment Adherence in Inflammatory Bowel Disease Patients from Argentina: A Multicenter Study

Juan Lasa, Gustavo Correa, Claudia Fuxman, Laura Garbi, Maria Eugenia Linares, Pablo Lubrano, Astrid Rausch, Martin Toro, Martin Yantorno, Ignacio Zubiaurre, Laurent Peyrin-Biroulet, Pablo Olivera, Juan Lasa, Gustavo Correa, Claudia Fuxman, Laura Garbi, Maria Eugenia Linares, Pablo Lubrano, Astrid Rausch, Martin Toro, Martin Yantorno, Ignacio Zubiaurre, Laurent Peyrin-Biroulet, Pablo Olivera

Abstract

Methods: A multicenter cross-sectional study involving seven referral centers from three cities of Argentina was undertaken. Patients with a diagnosis of ulcerative colitis (UC), Crohn's disease (CD), or indeterminate colitis (IBDU/IC) were invited to answer an anonymous survey, which included a 5-point Likert scale to evaluate adherence to therapies. Independent variables associated with inadequate adherence were evaluated.

Results: Overall, 447 UC/IBDU and 135 CD patients were enrolled. Median age was 37 years (range 21-72); 39.8% were male; median time from diagnosis was 6 years (0.5-35). 91.4% were under treatment with at least one oral medication; 50.3% of patients reported inadequate adherence to oral medications. Patients with UC/IBDU had a lower risk of inadequate adherence when compared to patients with CD (OR 0.57 (0.37-0.87)). 21.8% reported inadequate adherence to biologics; subcutaneous administration was significantly associated with inadequate adherence to biologics (OR 4.8 (1.57-14.66)).

Conclusion: Inadequate treatment adherence is common among patients with IBD, and potentially modifiable factors were identified.

Conflict of interest statement

CF and LG declare no conflict of interest. JL received consulting and lecture fees from Sanofi-Aventis. GC received consulting and lecture fees from Biotoscana, Ferring, Janssen, and Abbvie. MEL received consulting fees from Abbott and lecture fees from Takeda and Abbvie. PL received consulting and lecture fees from Takeda. AR received lecture fees from Takeda and Abbvie. MT received consulting and lecture fees from Takeda, Ferring, Janssen, and Abbvie. MY received lecture fees from Biotoscana, Ferring, and Abbvie. IZ received consulting and lecture fees from Ferring and Abbvie. LBP received consulting fees from Merck, Abbvie, Janssen, Genentech, Mitsubishi, Ferring, Norgine, Tillotts, Vifor, Therakos, Pharmacosmos, Pilège, BMS, UCB-pharma, Hospira, Celltrion, Takeda, Biogaran, Boehringer-Ingelheim, Lilly, Pfizer, HAC-Pharma, Index Pharmaceuticals, Amgen, and Sandoz and lecture fees from Merck, Abbvie, Takeda, Janssen, Ferring, Norgine, Tillotts, Vifor, Therakos, Mitsubishi, and HAC-pharma. PO received consulting fees from Abbvie and Takeda and lecture fees from Takeda. PL and PO received medical writing fees from Takeda Argentina.

Copyright © 2020 Juan Lasa et al.

Figures

Figure 1
Figure 1
Flow chart showing patient selection process.

References

    1. Ungaro R., Mehandru S., Allen P. B., Peyrin-Biroulet L., Colombel J.-F. Ulcerative colitis. Lancet. 2017;389(10080):1756–1770. doi: 10.1016/S0140-6736(16)32126-2.
    1. Torres J., Mehandru S., Colombel J.-F., Peyrin-Biroulet L. Crohn's disease. Lancet. 2016;389(10080):1741–1755. doi: 10.1016/S0140-6736(16)31711-1.
    1. Bryant R. V., Brain O., Travis S. P. L. Conventional drug therapy for inflammatory bowel disease. Scandinavian Journal of Gastroenterology. 2015;50(1):90–112. doi: 10.3109/00365521.2014.968864.
    1. Ananthakrishnan A. N. Personalizing therapy for inflammatory bowel diseases. Expert Review of Gastroenterology & Hepatology. 2013;7(6):549–558. doi: 10.1586/17474124.2013.824693.
    1. Buisson A., Seigne A.-L., DʼHuart M. C., Bigard M. A., Peyrin-Biroulet L. The extra burden of infliximab infusions in inflammatory bowel disease. Inflammatory Bowel Diseases. 2013;19(11):2464–2467. doi: 10.1097/MIB.0b013e3182a19268.
    1. Higgins P. D. R., Rubin D. T., Kaulback K., Schoenfield P. S., Kane S. V. Systematic review: impact of non-adherence to 5-aminosalicylic acid products on the frequency and cost of ulcerative colitis flares. Alimentary Pharmacology & Therapeutics. 2009;29(3):247–257. doi: 10.1111/j.1365-2036.2008.03865.x.
    1. Mitra D., Hodgkins P., Yen L., Davis K. L., Cohen R. D. Association between oral 5-ASA adherence and health care utilization and costs among patients with active ulcerative colitis. BMC Gastroenterology. 2012;12:p. 132. doi: 10.1186/1471-230X-12-132.
    1. Kane S. V., Chao J., Mulani P. M. Adherence to infliximab maintenance therapy and health care utilization and costs by Crohn’s disease patients. Advances in Therapy. 2009;26(10):936–946. doi: 10.1007/s12325-009-0069-7.
    1. Kane S., Shaya F. Medication non-adherence is associated with increased medical health care costs. Digestive Diseases and Sciences. 2008;53(4):1020–1024. doi: 10.1007/s10620-007-9968-0.
    1. Perry J., Chen A., Kariyawasam V., et al. Medication non-adherence in inflammatory bowel diseases is associated with disability. Intestinal research. 2018;16(4):571–578. doi: 10.5217/ir.2018.00033.
    1. Kane S. V., Cohen R. D., Aikens J. E., Hanauer S. B. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. The American Journal of Gastroenterology. 2001;96(10):2929–2933. doi: 10.1111/j.1572-0241.2001.04683.x.
    1. Shale M. J., Riley S. A. Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease. Alimentary Pharmacology & Therapeutics. 2003;18(2):191–198. doi: 10.1046/j.1365-2036.2003.01648.x.
    1. Sewitch M. J., Abrahamowicz M., Barkun A., et al. Patient nonadherence to medication in inflammatory bowel disease. The American Journal of Gastroenterology. 2003;98(7):1535–1544. doi: 10.1111/j.1572-0241.2003.07522.x.
    1. Ediger J. P., Walker J. R., Graff L., et al. Predictors of medication adherence in inflammatory bowel disease. The American Journal of Gastroenterology. 2007;102(7):1417–1426. doi: 10.1111/j.1572-0241.2007.01212.x.
    1. D’Incà R., Bertomoro P., Mazzocco K., Vettorato M. G., Rumiati R., Sturniolo G. C. Risk factors for non-adherence to medication in inflammatory bowel disease patients. Alimentary Pharmacology & Therapeutics. 2008;27(2):166–172. doi: 10.1111/j.1365-2036.2007.03555.x.
    1. Ma C., Evaschesen C. J., Gracias G., et al. Inflammatory bowel disease patients are frequently nonadherent to scheduled induction and maintenance infliximab therapy: a Canadian cohort study. Canadian Journal of Gastroenterology and Hepatology. 2015;29(6):314. doi: 10.1155/2015/378628.
    1. Wentworth B. J., Buerlein R. C. D., Tuskey A. G., Overby M. A., Smolkin M. E., Behm B. W. Nonadherence to Biologic Therapies in Inflammatory Bowel Disease. Inflammatory Bowel Diseases. 2018;24(9):2053–2061. doi: 10.1093/ibd/izy102.
    1. Lopez A., Billioud V., Peyrin-Biroulet C., Peyrin-Biroulet L. Adherence to anti-TNF therapy in inflammatory bowel diseases: a systematic review. Inflammatory Bowel Diseases. 2013;19(7):1528–1533. doi: 10.1097/MIB.0b013e31828132cb.
    1. Moradkhani A., Kerwin L., Dudley-Brown S., Tabibian J. H. Disease-specific knowledge, coping, and adherence in patients with inflammatory bowel disease. Digestive Diseases and Sciences. 2011;56(10):2972–2977. doi: 10.1007/s10620-011-1714-y.
    1. Leong R. W. L., Lawrance I. C., Ching J. Y. L., et al. Knowledge, quality of life, and use of complementary and alternative medicine and therapies in inflammatory bowel disease: a comparison of Chinese and Caucasian patients. Digestive Diseases and Sciences. 2004;49(10):1672–1676. doi: 10.1023/b:ddas.0000043384.26092.f4.
    1. Blumenstein I., McDermott E., Keegan D., et al. Sources of information and factual knowledge in Europeans with inflammatory bowel diseases: a cross-cultural comparison between German and Irish patients. Journal of Crohn's & Colitis. 2013;7(9):e331–e336. doi: 10.1016/j.crohns.2013.01.006.
    1. Bernal I., Domènech E., Garcia-Planella E., et al. Medication-taking behavior in a cohort of patients with inflammatory bowel disease. Digestive Diseases and Sciences. 2006;51(12):2165–2169. doi: 10.1007/s10620-006-9444-2.
    1. Cervený P., Bortlík M., Kubena A., Vlcek J., Lakatos P. L., Lukás M. Nonadherence in inflammatory bowel disease: results of factor analysis. Inflammatory Bowel Diseases. 2007;13(10):1244–1249. doi: 10.1002/ibd.20189.
    1. Loftus E. V. A practical perspective on ulcerative colitis: patients’ needs from aminosalicylate therapies. Inflammatory Bowel Diseases. 2006;12(12):1107–1113. doi: 10.1097/01.mib.0000235831.01682.8d.
    1. Moshkovska T., Stone M. A., Clatworthy J., et al. An investigation of medication adherence to 5-aminosalicylic acid therapy in patients with ulcerative colitis, using self-report and urinary drug excretion measurements. Alimentary Pharmacology & Therapeutics. 2009;30(11-12):1118–1127. doi: 10.1111/j.1365-2036.2009.04152.x.
    1. Bermejo F., López-San Román A., Algaba A., et al. Factors that modify therapy adherence in patients with inflammatory bowel disease. Journal of Crohn's & Colitis. 2010;4(4):422–426. doi: 10.1016/j.crohns.2010.01.005.
    1. Bokemeyer B., Teml A., Roggel C., et al. Adherence to thiopurine treatment in out-patients with Crohn’s disease. Alimentary Pharmacology & Therapeutics. 2007;26(2):217–225. doi: 10.1111/j.1365-2036.2007.03365.x.
    1. Selinger C. P., Eaden J., Jones D. B., et al. Modifiable factors associated with nonadherence to maintenance medication for inflammatory bowel disease. Inflammatory Bowel Diseases. 2013;19(10):2199–2206. doi: 10.1097/MIB.0b013e31829ed8a6.
    1. Campos S., Portela F., Sousa P., Sofia C. Inflammatory bowel disease: adherence to immunomodulators in a biological therapy era. European Journal of Gastroenterology & Hepatology. 2016;28(11):1313–1319. doi: 10.1097/MEG.0000000000000704.
    1. Wright S., Sanders D. S., Lobo A. J., Lennard L. Clinical significance of azathioprine active metabolite concentrations in inflammatory bowel disease. Gut. 2004;53(8):1123–1128. doi: 10.1136/gut.2003.032896.
    1. Hess L. M., Raebel M. A., Conner D. A., Malone D. C. Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures. Annals of Pharmacotherapy. 2016;40(7-8):1280–1288. doi: 10.1345/aph.1H018.
    1. Bager P., Julsgaard M., Vestergaard T., Christensen L. A., Dahlerup J. F. Adherence and quality of care in IBD. Scandinavian Journal of Gastroenterology. 2016;51(11):1326–1331. doi: 10.1080/00365521.2016.1195870.
    1. Kemp K., Dibley L., Chauhan U., et al. Second N-ECCO Consensus Statements on the European Nursing Roles in Caring for Patients with Crohn’s Disease or Ulcerative Colitis. Journal of Crohn's & Colitis. 2018;12(7):760–776. doi: 10.1093/ecco-jcc/jjy020.
    1. Ferreira R. A., Barreto S. M., Giatti L. Hipertensão arterial referida e utilização de medicamentos de uso contínuo no Brasil: um estudo de base populacional. Cadernos de Saúde Pública. 2014;30(4):815–826. doi: 10.1590/0102-311X00160512.
    1. Correa G., Fuxman C., Garbi L., et al. Treatment adherence in inflammatory bowel disease patients from Argentina: a multicenter study. United European Gastroenterology Week. 2018, .
    1. Lenti M. V., Selinger C. P. Medication non-adherence in adult patients affected by inflammatory bowel disease: a critical review and update of the determining factors, consequences and possible interventions. Expert Review of Gastroenterology & Hepatology. 2017;11(3):215–226. doi: 10.1080/17474124.2017.1284587.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다